B&G Foods, Inc.
active
Latest developmentThe Nortera sale ended; the broader alternatives process continues.Sources through Oct 6, 2026
Next to watchA subsequent strategic decisionTiming not announced
Open research brief →DISCOVER / COMPARE / INVESTIGATE
Situation database
Compare disclosed developments, event status, and the next point to monitor.
9 results · All published stages
| Company / situation | Current state | Latest development | Next to watch |
|---|---|---|---|
| B&G Foods, Inc. →Automated research | active Strategic review Asset saleAlternatives remain under evaluation | The Nortera sale ended; the broader alternatives process continues. Sources through Oct 6, 2026 | A subsequent strategic decision Timing not announced |
| Caribou Biosciences, Inc. →Automated research | active Strategic review RestructuringStrategic alternatives under evaluation | The board approved the review and restructuring on October 2. Sources through Oct 6, 2026 | A subsequent strategic decision Timing not announced |
| Designer Brands Inc. →Automated research | active Activism Active shareholder engagement | Stone House maintained 7,000,000 shares and published an expanded Topo value-creation thesis Sources through Sep 15, 2026 | Next company response or ownership amendment Next earnings call, proxy filing or Schedule 13D amendment |
| GE Vernova Inc. →Automated research | completed Spin-off Standalone operations and separation-obligation unwind | GE completed the GE Vernova distribution on April 2, 2024 at one GE Vernova share for every four GE shares. Sources through Aug 27, 2026 | Claire McDonough joins as strategic advisor Nov 1, 2026 |
| Southwest Airlines Co. →Automated research | active Activism Post-cooperation execution monitoring | Southwest continued to report incremental advisory expense related to activist investor activities Sources through Jul 23, 2026 | Next ownership or operating update Next Schedule 13D amendment or quarterly filing |
| Incyte Corporation →Reviewed research | completed Tender offer Tender completed | The final results state that 29,821,563 shares were properly tendered at or below $60 and that Incyte accepted 27,866,666 shares at $60 for approximately $1.672 billion, excluding fees and expenses. Sources through Jun 13, 2024 | Capital allocation and post-repurchase share-count disclosure Next periodic capital-allocation update |
| Solventum Corporation →Reviewed research | completed Spin-off Distribution completed | Solventum's third-quarter 10-Q states that the spin-off was completed on April 1, 2024 through the 80.1% distribution, 172,709,505 shares were issued, and Solventum became an independent public company. Sources through Nov 8, 2024 | Post-separation liabilities and retained-stake disclosures Ongoing periodic filings |
| Sonim Technologies, Inc. →Reviewed research | completed M&A Asset sale reported completed; company renamed DNA X | It signed an agreement to sell substantially all enterprise 5G assets to a Social Mobile subsidiary for $15 million and later reported completion of the disposition and a corporate name change to DNA X. Sources through Jan 23, 2026 | No scheduled transaction catalyst; monitor post-closing disclosures No announced transaction timetable |
| STAAR Surgical Company →Reviewed research | terminated M&A Terminated after stockholder vote | Stockholders voted against the merger on January 6, 2026, and STAAR's subsequent 10-K states that the merger agreement terminated effective that date. Sources through Mar 3, 2026 | No scheduled merger catalyst; monitor standalone disclosures No announced transaction timetable |
Caribou Biosciences, Inc.
active
Latest developmentThe board approved the review and restructuring on October 2.Sources through Oct 6, 2026
Next to watchA subsequent strategic decisionTiming not announced
Open research brief →Designer Brands Inc.
active
Latest developmentStone House maintained 7,000,000 shares and published an expanded Topo value-creation thesisSources through Sep 15, 2026
Next to watchNext company response or ownership amendmentNext earnings call, proxy filing or Schedule 13D amendment
Open research brief →GE Vernova Inc.
completed
Latest developmentGE completed the GE Vernova distribution on April 2, 2024 at one GE Vernova share for every four GE shares.Sources through Aug 27, 2026
Next to watchClaire McDonough joins as strategic advisorNov 1, 2026
Open research brief →Southwest Airlines Co.
active
Latest developmentSouthwest continued to report incremental advisory expense related to activist investor activitiesSources through Jul 23, 2026
Next to watchNext ownership or operating updateNext Schedule 13D amendment or quarterly filing
Open research brief →Incyte Corporation
completed
Latest developmentThe final results state that 29,821,563 shares were properly tendered at or below $60 and that Incyte accepted 27,866,666 shares at $60 for approximately $1.672 billion, excluding fees and expenses.Sources through Jun 13, 2024
Next to watchCapital allocation and post-repurchase share-count disclosureNext periodic capital-allocation update
Open research brief →Solventum Corporation
completed
Latest developmentSolventum's third-quarter 10-Q states that the spin-off was completed on April 1, 2024 through the 80.1% distribution, 172,709,505 shares were issued, and Solventum became an independent public company.Sources through Nov 8, 2024
Next to watchPost-separation liabilities and retained-stake disclosuresOngoing periodic filings
Open research brief →Sonim Technologies, Inc.
completed
Latest developmentIt signed an agreement to sell substantially all enterprise 5G assets to a Social Mobile subsidiary for $15 million and later reported completion of the disposition and a corporate name change to DNA X.Sources through Jan 23, 2026
Next to watchNo scheduled transaction catalyst; monitor post-closing disclosuresNo announced transaction timetable
Open research brief →STAAR Surgical Company
terminated
Latest developmentStockholders voted against the merger on January 6, 2026, and STAAR's subsequent 10-K states that the merger agreement terminated effective that date.Sources through Mar 3, 2026
Next to watchNo scheduled merger catalyst; monitor standalone disclosuresNo announced transaction timetable
Open research brief →